Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)
Ramucirumab plus docetaxel is a promising and safe treatment option for previously treated patients with NSCLC and MPE, showing a high pleural effusion control rate.
Authors
- Noritaka Honda
- Kazumasa Akagi (ORCID: https://orcid.org/0000-0002-5487-0453)
- Hiromi Tomono (ORCID: https://orcid.org/0009-0006-2748-9418)
- Ryosuke Ogata
- Hiroshi Gyotoku (ORCID: https://orcid.org/0000-0002-5026-8078)
- Nanae Sugasaki
- Shinnosuke Takemoto (ORCID: https://orcid.org/0000-0003-0373-0618)
- Hirokazu Taniguchi (ORCID: https://orcid.org/0000-0003-2414-8344)
- Akitoshi Kinoshita (ORCID: https://orcid.org/0000-0001-6365-3381)
- Fumiko Hayashi
- Hiroshi Soda (ORCID: https://orcid.org/0000-0003-4993-1837)
- Katsumi Nakatomi
- Takayuki Suyama (ORCID: https://orcid.org/0000-0002-6986-411X)
- Hiroshi Mukae (ORCID: https://orcid.org/0000-0002-1429-5706)
- Midori Matsuo
- Hiroaki Senju
- Takaya Ikeda (ORCID: https://orcid.org/0000-0001-9585-1753)
- Sawana Ono
- Minoru Fukuda (ORCID: https://orcid.org/0000-0002-5321-1843)
- Seiji Nagashima
- Yosuke Dotsu
- Eisuke Sasaki
Institutions
- Nagasaki Prefectural Shimabara High School (JP)
- Sasebo City General Hospital (JP)
- Nagasaki Medical Center (JP)
- Senju Pharmaceutical (Japan) (JP)
- National Hospital Organization (JP)
- Ureshino Medical Center (JP)
- Nagasaki University Hospital (JP)
- Nagasaki University (JP)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-508
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Eli Lilly and Company
- Eli Lilly Japan